AU2020215177A1 — Methods of treating prostate cancer based on molecular subtypes

USPTO Abstract

Provided are methods of treating prostate cancer in a human male comprising administration of apalutamide and androgen deprivation therapy to a human male having prostate cancer (e.g., nmCRPC) if a biological sample obtained from the human male is determined to have a specific molecular subtype of prostate cancer, a specific classifier score, or increased or decreased expression of a signature class. The molecular subtypes include luminal-like or basal-like molecular subtype. Also provided are methods of using molecular signatures and genomic classifier scores, such as four co-regulated signature classes, metastasis risk based on a genomic classifier score, or a combination thereof, as prognostic indicators of apalutamide and androgen deprivation therapy in human males having prostate cancer, for improved treatment benefit.